REDWOOD CITY, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the second quarter 2024 on Thursday, August 8, 2024. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Seer is a life sciences company developing transformative products that open a new gateway to the proteome. Se ...

Core Insights - Strategic Environmental & Energy Resources, Inc. (SEER) has received a purchase order worth approximately $600,000 from Biochar Now, LLC (BCN) for the provision of kilns as part of BCN's nationwide expansion program [1][6] - BCN, in collaboration with AgriCap Group, LLC, has launched an "Insured Carbon" program that offers fully insured biochar carbon credits, enhancing the reliability and marketability of its carbon credits in the global market [2][11] - SEER is actively pursuing the establishment of a joint venture facility in Texas with BCN to produce biochar and is exploring the processing of fiberglass waste and other composites at this facility [3][12] Company Overview - SEER specializes in identifying, securing, and commercializing patented environmental clean technologies across various sectors, including oil & gas, renewable fuels, and waste management [4] - The company operates through two wholly-owned subsidiaries and two majority-owned subsidiaries, focusing on minimizing hazardous waste streams and processing waste into renewable fuels [4] Strategic Partnerships and Growth - SEER's collaboration with BCN is aimed at developing cost-effective kiln manufacturing processes to enhance biochar production efficiency and minimize capital expenditures for new production sites [6][10] - BCN has established five operational locations and is developing additional biochar production sites across North America and Southeast Asia, indicating a strong growth trajectory [6] - SEER's involvement in the biochar market is expected to create multiple revenue streams, including kiln sales, product sales, and carbon credit sales, thereby increasing shareholder equity [12]

Core Insights - Seer, Inc. has highlighted the impact of spaceflight on human physiology through recent studies, showcasing its Proteograph technology's ability to uncover significant proteomic changes [5][6][10] Group 1: Seer's Technology and Products - Seer's Proteograph XT Assay Kit enables rapid and unbiased proteomics research, capable of detecting over 60,000 peptides and 8,000 proteins in human plasma studies [3][8] - The Proteograph Product Suite integrates engineered nanoparticles, consumables, and software for deep proteomic analysis, designed for efficiency and ease of use in various laboratory settings [8] - The technology has been utilized to identify 23,164 peptides mapping to 2,992 unique protein groups, demonstrating its capability in high-resolution proteomic profiling [7] Group 2: Research Findings - Studies from the SpaceX Inspiration4 mission revealed acute changes in oxidative stress, brain homeostasis, and coagulation, with some protein alterations persisting six months post-mission [2][6] - The research indicates significant alterations in proteins related to coagulation, wound healing, antioxidation, and brain function, emphasizing the physiological impacts of spaceflight [2][6] - The findings contribute to a comprehensive atlas of molecular and physiological profiles from multiple space missions, providing valuable data for future aerospace research [10][11] Group 3: Collaboration and Future Directions - Collaboration between Seer and researchers has led to the identification of novel protein metrics, potentially paving the way for new therapeutic and biomarker discovery [11] - The studies aim to monitor physiological changes over time, which could inform the development of personalized countermeasures for astronauts [11]

Secretome profiles from SpaceX Inspiration4 mission show alterations in oxidative stress, brain homeostasis, and coagulation Omid Farokhzad, M.D., Chair & Chief Executive Officer of Seer said, "Exploring the effects of space flight on the human body presents an intriguing frontier for proteomic research. These papers highlight Seer's technology to provide unbiased insights into the proteome and shed light on dysfunctional biological alterations. At Seer, we empower researchers in detecting proteins and pept ...

REDWOOD CITY, Calif., June 02, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, announced today that PrognomiQ has completed the largest and deepest unbiased mass spectrometry plasma biomarker study to date utilizing the Seer Proteograph™ Product Suite and Thermo Fisher Scientific's Thermo Scientific™ Orbitrap™ Astral™ mass spectrometer. This pioneering research involved a multi-cancer case-control cohort of 2,840 su ...

Seer, Inc. (NASDAQ:SEER) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Carrie Mendivil - Investor Relations Omid Farokhzad - Chief Executive Officer & Chair David Horn - President & Chief Financial Officer Conference Call Participants Yuko Oku - Morgan Stanley Operator Good day and thank you for standing by. Welcome to the Seer, Inc. First Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there wi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission file number 001-39747 SEER, INC. (Exact name of Registrant as specified in its charter) (State or other juri ...

Seer Reports First Quarter 2024 Financial Results Demonstrated the power of the Proteograph Product Suite with a growing number of customer presentations and publications REDWOOD CITY, Calif. May 8, 2024 – Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the first quarter ended March 31, 2024. Recent Highlights "We are committed to reducing barriers to the commercial adoption of our differentiated techno ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) 3800 Bridge Parkway, ...

Seer, Inc. (NASDAQ:SEER) Q4 2023 Earnings Conference Call February 29, 2024 4:30 PM ET Company Participants Carrie Mendivil - IR Omid Farokhzad - Chair & CEO David Horn - President & CFO Conference Call Participants Dan Brennan - TD Cowen Tejas Savant - Morgan Stanley Marta Nazarovets - JPMorgan Chase Operator Thank you for standing by, and welcome to the Seer Fourth Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will ...